BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
125 results:

  • 1. State-of-the-Art Advancements in Gastroesophageal cancer Treatment: Harnessing Biomarkers for Precision Care.
    Balmaceda NB; Petrillo A; Krishnan M; Zhao JJ; Kim S; Klute KA; Sundar R
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431060. PubMed ID: 38771996
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Uncommon molecular alterations in follicular-derived thyroid carcinoma: A single institution study.
    Alexiev BA; Vormittag-Nocito ER; Lorch J; Yeldandi A; Buttars PR; Jennings LJ
    Pathol Res Pract; 2024 Jun; 258():155355. PubMed ID: 38763089
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to fgfr2.
    Liu F; Tang L; Liu H; Chen Y; Xiao T; Gu W; Yang H; Wang H; Chen P
    Cell Death Dis; 2024 Apr; 15(4):279. PubMed ID: 38637504
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. "Examining the link between tooth agenesis and papillary thyroid cancer: is there a risk factor?" Observational study.
    Matošić Ž; Šimunović L; Jukić T; Granić R; Meštrović S
    Prog Orthod; 2024 Mar; 25(1):12. PubMed ID: 38523193
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
    Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
    Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
    Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
    JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. FGFR1/2/3-rearranged carcinoma of the head and neck: expanded histological spectrum crossing path with high-risk HPV in the sinonasal tract.
    Chu YH; Mullaney K; DiNapoli SE; Cohen MA; Xu B; Ghossein R; Katabi N; Dogan S
    Histopathology; 2024 Mar; 84(4):589-600. PubMed ID: 38010295
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Molecular characterisation of tumours of the lacrimal apparatus.
    Vibert R; Cyrta J; Girard E; Vacher S; Dupain C; Antonio S; Wong J; Baulande S; De Sousa JMF; Vincent-Salomon A; Masliah-Planchon J; Girard N; Le Tourneau C; Kamal M; Bièche I
    Histopathology; 2023 Dec; 83(6):925-935. PubMed ID: 37706251
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.
    Liang WW; Lu RJ; Jayasinghe RG; Foltz SM; Porta-Pardo E; Geffen Y; Wendl MC; Lazcano R; Kolodziejczak I; Song Y; Govindan A; Demicco EG; Li X; Li Y; Sethuraman S; Payne SH; Fenyö D; Rodriguez H; Wiznerowicz M; Shen H; Mani DR; Rodland KD; Lazar AJ; Robles AI; Ding L;
    Cancer Cell; 2023 Sep; 41(9):1567-1585.e7. PubMed ID: 37582362
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
    Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
    Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
    Javle M; King G; Spencer K; Borad MJ
    Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal cancers.
    Lee MS; Kaseb AO; Pant S
    Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Chondrosarcoma with Target-Like Chondrocytes: Update on Molecular Profiling and Specific Morphological Features.
    Povýšil C; Hojný J; Kaňa M
    Folia Biol (Praha); 2022; 68(3):112-124. PubMed ID: 36689318
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. fgfr2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
    Albin J; Fahrig L; Siemanowski J; Rehkaemper J; Gebauer F; Zander T; Buettner R; Bruns CJ; Schroeder W; Alakus H; Hieggelke L; Quaas A
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5289-5300. PubMed ID: 36416959
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Oesogastric cancer - new therapeutic targets].
    Palmieri LJ; Soubeyran I; Pernot S
    Bull Cancer; 2023 May; 110(5):560-569. PubMed ID: 36371284
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. N-nitrosamines-mediated downregulation of LncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of fgfr2.
    Wang X; Sun M; Gao Z; Yin L; Pu Y; Zhu Y; Wang X; Liu R
    Sci Total Environ; 2023 Jan; 855():158918. PubMed ID: 36169023
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Identification and characterization of fgfr2
    Qiu H; Zhang X; Qi J; Zhang J; Tong Y; Li L; Fu L; Qin YR; Guan X; Zhang L
    J Exp Clin Cancer Res; 2022 Aug; 41(1):240. PubMed ID: 35941662
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Identification of potential biomarkers and survival analysis for oral squamous cell carcinoma: A transcriptomic study.
    de Paula Souza DPS; Dos Reis Pereira Queiroz L; de Souza MG; de Jesus SF; Gomes ESB; Vitorino RT; Santos SHS; Farias LC; de Paula AMB; D'Angelo MFSV; de Carvalho Fraga CA; Guimarães ALS
    Oral Dis; 2023 Oct; 29(7):2658-2666. PubMed ID: 35796645
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Precision medicine: Sustained response to erdafitinib in fgfr2-mutant, multiply recurrent ameloblastoma.
    Lawson-Michod KA; Le CH; Tranesh G; Thomas PC; Bauman JE
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1656. PubMed ID: 35761436
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies.
    Kleo K; Jovanovic VM; Arndold A; Lehmann A; Lammert H; Berg E; Harloff H; Treese C; Hummel M; Daum S
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1049-1061. PubMed ID: 35246724
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.